Rare-disease patients gain faster access to evidence-based treatments

What it does

This bill expands Medicare, Medicaid, and private health insurance coverage for drugs treating rare diseases (affecting 200,000 or fewer people in the U.S.) by allowing coverage based on peer-reviewed medical literature and clinical guidelines, not just FDA-approved labeling. It also requires health insurers to provide expedited appeals for denials of coverage for such rare-disease drugs. Patients with rare conditions and their doctors benefit by gaining faster access to off-label treatments supported by medical evidence.

Why we flagged it

The bill's core mechanism is to broaden insurance coverage and expedite appeals for drugs treating rare diseases, supported by medical evidence beyond FDA labeling. This is a patient-access and procedural-rights measure, not a deregulation or subsidy.

What the text implies

• Expedited appeals process may create administrative burden on insurers, potentially raising premiums or reducing insurer profitability in the rare-disease segment.
• Reliance on peer-reviewed literature and clinical guidelines as coverage triggers may incentivize pharmaceutical companies to fund or publish studies supporting off-label uses, creating potential conflicts of interest in medical literature.
• The 200,000-person threshold is arbitrary and may not align with clinical definitions of 'rare disease' (typically <5 in 10,000 or ~1,500 people), potentially expanding coverage beyond intended scope.
• Medicaid conforming amendment changes 'compendia' to 'sources,' broadening what counts as evidence for coverage, which may increase state Medicaid costs without explicit appropriation.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with rare diseases gain expanded access to evidence-based treatments and faster appeals of coverage denials, reducing barriers to care for a vulnerable population. The bill does not impose new costs on patients or restrict existing rights; it broadens coverage and procedural protections.

Who stands to gain

• pharmaceutical manufacturers of rare-disease drugs
• specialty pharmaceutical companies
• biotech firms developing orphan drugs

Named in the bill

Medicare, Medicaid, FDA (Food and Drug Administration), PHSA (Public Health Service Act), ERISA (Employee Retirement Income Security Act), IRC (Internal Revenue Code), Section 1861(t)(2) Social Security Act, Section 1927(k)(6) Social Security Act, Section 2799A-11 PHSA, Section 736 ERISA, Section 9826 IRC

Where it stands

1 cosponsor: 1 Democrats.

• Dec 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Dec 17, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $70,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Thom Tillis, the sponsor, reported $973,475 in PAC receipts in the 2026 cycle. $-5,000 of that came from 1 PAC tied to these lobbying clients.

• The Home Depot — $70,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.